EnerSpar Corp. (TSE:NRX) has released an update.
NurExone Biologic Inc. has achieved a significant milestone with the FDA’s orphan-drug designation for its ExoPTEN therapy for acute Spinal Cord Injury, which promises exclusive market rights and other benefits upon approval. The company is bolstering R&D efforts with new in-house facilities and preclinical testing, and it has secured approximately C$4.0 million from warrant exercises to fund operations through 2024. Despite increased R&D spending, NurExone remains in a growth stage without product commercialization and is reliant on financing activities.
For further insights into TSE:NRX stock, check out TipRanks’ Stock Analysis page.
